Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial

Smith, Ian; Robertson, J.F.R.; Kilburn, Lucy; Wilcox, Maggie; Evans, Abigail; Holcombe, Chris; Horgan, Kieran; Kirwan, Cliona; Mallon, Elizabeth; Sibbering, Mark; Skene, Anthony; Vidya, Raghavan; C.U. Cheang, Maggie; Banerji, Jane; P. Morden, James; Sidhu, Kally; Dodson, Andrew; M. Bliss, Judith; Dowsett, Mitch

doi:10.1016/s1470-2045(20)30458-7

Public

Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial

Published in The Lancet Oncology • Nov 1, 2020

Authors:

Ian Smith

J.F.R. Robertson

Lucy Kilburn

Abstract

Background Preoperative and perioperative aromatase inhibitor (POAI) therapy has the potential to improve outcomes in women with operable oestrogen receptor-positive primary breast cancer. It has also been suggested that tumour Ki67 values after 2 weeks (Ki67 2W ) of POAI predicts individual patient...

Subject

Medicine

Clinical endpoint

Letrozole

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!